CDK2 and breast carcinoma: The ten-year overall survival of patients with primary breast cancers with high expression (defined as that of the upper quartile of the cohort) of cyclin E and CDK2 was significantly lower than for patients whose cancer lesions showed medium/low expression (publicly available KM plotter cohort, Suppl.